GT
CYCN icon

Glenmede Trust’s Cyclerion Therapeutics CYCN Stock Holding History

Glenmede Trust’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10
Closed -$1K – 1471
2020
Q3 		$1K Hold
10
– – ﹤0.01% 2332
2020
Q2 		$1K Hold
10
– – ﹤0.01% 2315
2020
Q1 		$0 Hold
10
– – ﹤0.01% 3018
2019
Q4 		$0 Hold
10
– – ﹤0.01% 3033
2019
Q3 		$2 Hold
10
– – ﹤0.01% 2842
2019
Q2 		$2 Buy
+10
New +$2.83K ﹤0.01% 2845

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Trust's CYCN Position: Q4 2020 in Review

Glenmede Trust sold out of Cyclerion Therapeutics (CYCN) in Q4 2020, closing a stake of 10 shares — an estimated $1K sold.

Glenmede Trust first reported a position in CYCN in Q2 2019 and held it in 6 quarters. The position peaked at $1K in Q3 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q4 2020.

  • Glenmede Trust reported no remaining Cyclerion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 10 Cyclerion Therapeutics shares in Q4 2020, an estimated $1K.
  • Glenmede Trust first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 6 quarters.
  • Glenmede Trust's Cyclerion Therapeutics position peaked at $1K in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.